TANG CAPITAL MANAGEMENT LLC
13F Reported Value
ⓘ$2.0B
Holdings
51
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
TANG CAPITAL MANAGEMENT LLC disclosed 51 positions worth $2.0B in its Form 13F-HR for Q1 2026, led by $AUPH (Aurinia Pharmaceuticals Inc.) at 9.2% of the equity portfolio, followed by $CELC and $MIRM. During the quarter the fund opened 4 new positions and exited 28 — including a new stake in $CMPS and a full exit from $RNA. The portfolio is most concentrated in Healthcare (88.7% of disclosed assets). All figures are sourced directly from TANG CAPITAL MANAGEMENT LLC’s Form 13F-HR filing with the SEC under CIK 1232621.
AI Fund Analysis
Concentrating
$AUPH
$MIRM
$KNSA
$PTCT
$IMCR
$CBIO
$CAPR
$ANIP
$CMPSSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 73.3#200
Quality
$181.2M12,229,500 sh - —
Quality
$119.8M1,050,000 sh - 32.7#2,252
Quality
$114.2M1,236,027 sh GALAPAGOS NV
—Quality
$113.6M3,785,991 sh- —
Quality
$109.3M168,000 sh - $108.8M2,259,889 sh
- —
Quality
$103.4M3,399,900 sh - 80.0
Quality
$102.2M1,500,000 sh - —
Quality
$95.4M1,892,200 sh - 25.9
Quality
$92.1M4,573,530 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.$AUPH | 73.3#200 | $181.2M | 12,229,500 |
 Celcuity Inc.$CELC | — | $119.8M | 1,050,000 |
| Mirum Pharmaceuticals, Inc.$MIRM | 32.7#2,252 | $114.2M | 1,236,027 |
| GALAPAGOS NV | — | $113.6M | 3,785,991 |
 SPDR S&P 500 ETF TRUST$SPY | — | $109.3M | 168,000 |
| Kiniksa Pharmaceuticals International, plc$KNSA | — | $108.8M | 2,259,889 |
| CAPRICOR THERAPEUTICS, INC.$CAPR | — | $103.4M | 3,399,900 |
| PTC THERAPEUTICS, INC.$PTCT | 80.0 | $102.2M | 1,500,000 |
 Spyre Therapeutics, Inc.$SYRE | — | $95.4M | 1,892,200 |
 KalVista Pharmaceuticals, Inc.$KALV | 25.9 | $92.1M | 4,573,530 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of TANG CAPITAL MANAGEMENT LLC's 51 positions.
Showing top 10 of 51 holdings.
Sector Allocation
Healthcare
$1.7B
Other
$222.8M
Full Holdings — TANG CAPITAL MANAGEMENT LLC (Q1 2026)
All 51 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AUPH | Aurinia Pharmaceuticals Inc. | $181.2M | 9.2% | +8% | 73.3 |
| 2 | $CELC | Celcuity Inc. | $119.8M | 6.1% | +0% | — |
| 3 | $MIRM | Mirum Pharmaceuticals, Inc. | $114.2M | 5.8% | +0% | 32.7 |
| 4 | — | GALAPAGOS NV | $113.6M | 5.8% | -3% | — |
| 5 | $SPY | SPDR S&P 500 ETF TRUST | $109.3M | 5.5% | +460% | — |
| 6 | $KNSA | Kiniksa Pharmaceuticals International, plc | $108.8M | 5.5% | +0% | — |
| 7 | $CAPR | CAPRICOR THERAPEUTICS, INC. | $103.4M | 5.3% | +100% | — |
| 8 | $PTCT | PTC THERAPEUTICS, INC. | $102.2M | 5.2% | +0% | 80 |
| 9 | $SYRE | Spyre Therapeutics, Inc. | $95.4M | 4.8% | +0% | — |
| 10 | $KALV | KalVista Pharmaceuticals, Inc. | $92.1M | 4.7% | +0% | 25.9 |
| 11 |  $CMPX | Compass Therapeutics, Inc. | $88.8M | 4.5% | +0% | — |
| 12 |  $TARS | Tarsus Pharmaceuticals, Inc. | $83.4M | 4.2% | +0% | 40.8 |
| 13 | $IMCR | Immunocore Holdings plc | $79.9M | 4.1% | +1% | — |
| 14 |  $ANAB | ANAPTYSBIO, INC | $73.8M | 3.8% | -0% | 29.4 |
| 15 |  $CORT | CORCEPT THERAPEUTICS INC | $60.5M | 3.1% | +857% | 55.4 |
| 16 | $ANIP | ANI PHARMACEUTICALS INC | $54.4M | 2.8% | +47% | 68.6 |
| 17 |  $INSM | INSMED Inc | $42.5M | 2.2% | +333% | 29.4 |
| 18 |  $BNTX | BioNTech SE | $41.8M | 2.1% | +0% | — |
| 19 |  $VRDN | Viridian Therapeutics, Inc.\DE | $35.1M | 1.8% | +0% | 30.5 |
| 20 |  $AVIR | Atea Pharmaceuticals, Inc. | $25.9M | 1.3% | +0% | — |
| 21 |  $PGEN | PRECIGEN, INC. | $24.8M | 1.3% | +14% | 38.6 |
| 22 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $22.2M | 1.1% | +0% | 26.8 |
| 23 | $CMPS | COMPASS Pathways plc | $22.1M | 1.1% | NEW | — |
| 24 | $CBIO | CRESCENT BIOPHARMA, INC. | $21.3M | 1.1% | +33% | 28 |
| 25 |  $STOK | Stoke Therapeutics, Inc. | $16.3M | 0.8% | +0% | 53.4 |
| 26 |  $VKTX | Viking Therapeutics, Inc. | $16.3M | 0.8% | +0% | — |
| 27 |  $IDYA | IDEAYA Biosciences, Inc. | $15.0M | 0.8% | +0% | 10.5 |
| 28 |  $NUVB | Nuvation Bio Inc. | $13.5M | 0.7% | -18% | 29.5 |
| 29 |  $PLRX | PLIANT THERAPEUTICS, INC. | $7.7M | 0.4% | +0% | — |
| 30 |  $DERM | Journey Medical Corp | $7.6M | 0.4% | -13% | 26.4 |
| 31 |  $JANX | Janux Therapeutics, Inc. | $7.0M | 0.3% | NEW | 24.8 |
| 32 |  $BIIB | BIOGEN INC. | $6.4M | 0.3% | +0% | 65.6 |
| 33 |  $URGN | UroGen Pharma Ltd. | $6.3M | 0.3% | +0% | — |
| 34 |  $ARVN | ARVINAS, INC. | $5.7M | 0.3% | -5% | 13.9 |
| 35 |  $PMVP | PMV Pharmaceuticals, Inc. | $5.3M | 0.3% | -14% | — |
| 36 |  $MRNA | Moderna, Inc. | $5.1M | 0.3% | -86% | 15.9 |
| 37 |  $HRTX | HERON THERAPEUTICS, INC. /DE/ | $5.0M | 0.3% | +0% | 30.6 |
| 38 |  $KZR | Kezar Life Sciences, Inc. | $4.9M | 0.3% | +0% | — |
| 39 |  $WVE | Wave Life Sciences Ltd. | $4.3M | 0.2% | +0% | — |
| 40 |  $LENZ | LENZ Therapeutics, Inc. | $4.1M | 0.2% | -48% | 19.6 |
| 41 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $3.4M | 0.2% | NEW | 26.3 |
| 42 |  $ERAS | Erasca, Inc. | $3.2M | 0.2% | -78% | — |
| 43 |  $CHRS | Coherus Oncology, Inc. | $3.2M | 0.2% | -31% | 42.9 |
| 44 |  $NKTX | Nkarta, Inc. | $3.1M | 0.2% | +0% | — |
| 45 |  $ALT | Altimmune, Inc. | $2.1M | 0.1% | -69% | 7.3 |
| 46 |  $EOLS | Evolus, Inc. | $2.0M | 0.1% | -61% | 30 |
| 47 |  $ABEO | ABEONA THERAPEUTICS INC. | $1.8M | 0.1% | -60% | 44.3 |
| 48 |  $FATE | FATE THERAPEUTICS INC | $1.4M | 0.1% | +0% | 6.7 |
| 49 |  $NMRA | Neumora Therapeutics, Inc. | $857,762 | 0.0% | -55% | — |
| 50 |  $LXRX | LEXICON PHARMACEUTICALS, INC. | $623,532 | 0.0% | NEW | 33.1 |
| 51 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $358,000 | 0.0% | +0% | — |
New Positions (4)
Exited Positions (28)
$RNA Avidity Biosciences, Inc.
$VRTX VERTEX PHARMACEUTICALS INC / MA
$TVTX Travere Therapeutics, Inc.
$VTYX Ventyx Biosciences, Inc.
$NVDA NVIDIA CORP
$META Meta Platforms, Inc.
$GSK GSK plc
$PCVX Vaxcyte, Inc.
$HRMY Harmony Biosciences Holdings, Inc.
$BMY BRISTOL MYERS SQUIBB CO
$TDOC Teladoc Health, Inc.
$DVAX DYNAVAX TECHNOLOGIES CORP
$VSTM Verastem, Inc.
$ACAD ACADIA PHARMACEUTICALS INC
$SRPT Sarepta Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for TANG CAPITAL MANAGEMENT LLC including:
Track TANG CAPITAL MANAGEMENT LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for TANG CAPITAL MANAGEMENT LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: TANG CAPITAL MANAGEMENT LLC
13F Pro is an AI hedge fund tracker and stock research platform. For TANG CAPITAL MANAGEMENT LLC (SEC CIK: 1232621), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in TANG CAPITAL MANAGEMENT LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.